| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Ko-143 | CTRPv2 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | 0.052 | 0.2 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | WH-4-023 | GDSC1000 | pan-cancer | AAC | -0.07 | 0.2 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | -0.076 | 0.2 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | HBX-41108 | CTRPv2 | pan-cancer | AAC | 0.054 | 0.2 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |